tetano
Editor, Senior Moderator
Proteomes
. 2021 Mar 1;9(1):12.
doi: 10.3390/proteomes9010012.
C1q Complement/Tumor Necrosis Factor-Associated Proteins in Cardiovascular Disease and COVID-19
Yaoli Xie[SUP] 1 2 [/SUP], Zhijun Meng[SUP] 1 2 [/SUP], Jia Gao[SUP] 2 [/SUP], Caihong Liu[SUP] 2 [/SUP], Jing Wang[SUP] 2 [/SUP], Rui Guo[SUP] 2 [/SUP], Jianli Zhao[SUP] 1 [/SUP], Bernard Lopez[SUP] 1 [/SUP], Theodore Christopher[SUP] 1 [/SUP], Daniel Lee[SUP] 1 [/SUP], Xinliang Ma[SUP] 1 [/SUP], Yajing Wang[SUP] 1 [/SUP]
Affiliations
Abstract
With continually improving treatment strategies and patient care, the overall mortality of cardiovascular disease (CVD) has been significantly reduced. However, this success is a double-edged sword, as many patients who survive cardiovascular complications will progress towards a chronic disorder over time. A family of adiponectin paralogs designated as C1q complement/tumor necrosis factor (TNF)-associated proteins (CTRPs) has been found to play a role in the development of CVD. CTRPs, which are comprised of 15 members, CTRP1 to CTRP15, are secreted from different organs/tissues and exhibit diverse functions, have attracted increasing attention because of their roles in maintaining inner homeostasis by regulating metabolism, inflammation, and immune surveillance. In particular, studies indicate that CTRPs participate in the progression of CVD, influencing its prognosis. This review aims to improve understanding of the role of CTRPs in the cardiovascular system by analyzing current knowledge. In particular, we examine the association of CTRPs with endothelial cell dysfunction, inflammation, and diabetes, which are the basis for development of CVD. Additionally, the recently emerged novel coronavirus (COVID-19), officially known as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been found to trigger severe cardiovascular injury in some patients, and evidence indicates that the mortality of COVID-19 is much higher in patients with CVD than without CVD. Understanding the relationship of CTRPs and the SARS-CoV-2-related damage to the cardiovascular system, as well as the potential mechanisms, will achieve a profound insight into a therapeutic strategy to effectively control CVD and reduce the mortality rate.
Keywords: COVID-19; CTRPs; cardiovascular disease; obesity.
. 2021 Mar 1;9(1):12.
doi: 10.3390/proteomes9010012.
C1q Complement/Tumor Necrosis Factor-Associated Proteins in Cardiovascular Disease and COVID-19
Yaoli Xie[SUP] 1 2 [/SUP], Zhijun Meng[SUP] 1 2 [/SUP], Jia Gao[SUP] 2 [/SUP], Caihong Liu[SUP] 2 [/SUP], Jing Wang[SUP] 2 [/SUP], Rui Guo[SUP] 2 [/SUP], Jianli Zhao[SUP] 1 [/SUP], Bernard Lopez[SUP] 1 [/SUP], Theodore Christopher[SUP] 1 [/SUP], Daniel Lee[SUP] 1 [/SUP], Xinliang Ma[SUP] 1 [/SUP], Yajing Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 33804408
- DOI: 10.3390/proteomes9010012
Abstract
With continually improving treatment strategies and patient care, the overall mortality of cardiovascular disease (CVD) has been significantly reduced. However, this success is a double-edged sword, as many patients who survive cardiovascular complications will progress towards a chronic disorder over time. A family of adiponectin paralogs designated as C1q complement/tumor necrosis factor (TNF)-associated proteins (CTRPs) has been found to play a role in the development of CVD. CTRPs, which are comprised of 15 members, CTRP1 to CTRP15, are secreted from different organs/tissues and exhibit diverse functions, have attracted increasing attention because of their roles in maintaining inner homeostasis by regulating metabolism, inflammation, and immune surveillance. In particular, studies indicate that CTRPs participate in the progression of CVD, influencing its prognosis. This review aims to improve understanding of the role of CTRPs in the cardiovascular system by analyzing current knowledge. In particular, we examine the association of CTRPs with endothelial cell dysfunction, inflammation, and diabetes, which are the basis for development of CVD. Additionally, the recently emerged novel coronavirus (COVID-19), officially known as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been found to trigger severe cardiovascular injury in some patients, and evidence indicates that the mortality of COVID-19 is much higher in patients with CVD than without CVD. Understanding the relationship of CTRPs and the SARS-CoV-2-related damage to the cardiovascular system, as well as the potential mechanisms, will achieve a profound insight into a therapeutic strategy to effectively control CVD and reduce the mortality rate.
Keywords: COVID-19; CTRPs; cardiovascular disease; obesity.